Adaptive Biotechnologies (ADPT) Stock Price

Adaptive Biotechnologies Price

NASDAQ·CLOSED
22.57USD-1.61 (-6.89 %)
Market closed

Revenue has compounded at 27.3% per year over the past 8 years to 265.20 M USD. Adaptive Biotechnologies's net margin stands at -22.4%, up from -134.3% several years earlier. Analysts set a median price target of 20.40 USD, implying 9.6% below the current price. Of 14 analysts, 12 rate the stock a buy — an overall Buy consensus. The stock trades about 91% above its 52-week low.

Adaptive Biotechnologies stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Adaptive Biotechnologies over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Adaptive Biotechnologies stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Adaptive Biotechnologies's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Adaptive Biotechnologies Stock Price History
DateAdaptive Biotechnologies Price
7/31/202622.57 USD
7/30/202624.18 USD
7/29/202622.07 USD
7/27/202622.12 USD
7/23/202622.31 USD
7/22/202621.95 USD
7/21/202622.58 USD
7/20/202621.86 USD
7/17/202622.92 USD
7/16/202622.10 USD
7/15/202622.90 USD
7/14/202622.90 USD
7/13/202622.59 USD
7/10/202622.50 USD
7/9/202623.30 USD
7/8/202621.78 USD
7/7/202622.25 USD
7/6/202623.21 USD
7/2/202622.64 USD
7/1/202623.90 USD
6/30/202622.92 USD
6/29/202623.04 USD
6/26/202622.40 USD
6/25/202621.64 USD
6/24/202620.67 USD
6/23/202618.41 USD
6/22/202618.65 USD
6/18/202618.43 USD
6/17/202618.02 USD
6/16/202619.05 USD
6/15/202618.84 USD
6/12/202619.11 USD
6/11/202619.82 USD
6/10/202619.05 USD
6/9/202618.55 USD
6/8/202617.85 USD
6/5/202618.22 USD
6/4/202618.71 USD
6/3/202616.29 USD
6/2/202615.99 USD
6/1/202616.46 USD
5/29/202616.46 USD
5/28/202615.84 USD
5/27/202614.73 USD
5/26/202615.01 USD
5/22/202614.75 USD
5/21/202614.78 USD
5/20/202614.26 USD
5/19/202613.85 USD
5/18/202613.58 USD
5/15/202613.71 USD
5/14/202614.08 USD
5/13/202614.03 USD
5/12/202614.56 USD
5/11/202614.47 USD
5/8/202614.76 USD
5/7/202615.70 USD
5/6/202615.42 USD
5/5/202614.73 USD
5/4/202615.49 USD
5/1/202615.25 USD
4/30/202615.07 USD
4/29/202614.46 USD
4/28/202615.00 USD
4/27/202615.18 USD
4/24/202615.11 USD
4/23/202614.77 USD
4/22/202615.17 USD
4/21/202615.18 USD
4/20/202615.58 USD
4/17/202615.46 USD
4/16/202615.05 USD
4/15/202615.53 USD
4/14/202615.53 USD
4/13/202615.10 USD
4/10/202613.67 USD
4/9/202614.32 USD
4/8/202615.86 USD
4/7/202614.65 USD
4/6/202615.05 USD
4/2/202615.83 USD
4/1/202615.42 USD
3/31/202614.83 USD
3/30/202613.73 USD
3/27/202613.26 USD
3/26/202614.92 USD
3/25/202614.92 USD
3/24/202615.12 USD
3/23/202614.85 USD
3/22/202614.60 USD
3/20/202614.51 USD
3/19/202614.51 USD
3/18/202614.43 USD
3/17/202614.19 USD
3/16/202614.31 USD
3/15/202614.23 USD
3/13/202614.07 USD
3/12/202614.07 USD
3/11/202613.30 USD
3/10/202615.20 USD
3/9/202615.52 USD
3/8/202615.98 USD
3/6/202615.88 USD
3/5/202615.88 USD
3/4/202617.02 USD
3/3/202617.57 USD
3/2/202617.18 USD
3/1/202617.23 USD
2/27/202617.12 USD
2/26/202617.12 USD
2/25/202617.59 USD
2/24/202617.32 USD
2/23/202617.15 USD
2/22/202616.45 USD
2/20/202616.24 USD
2/19/202616.24 USD
2/18/202617.15 USD
2/17/202616.96 USD
2/16/202616.87 USD
2/13/202617.14 USD
2/12/202617.14 USD
2/11/202616.61 USD
2/10/202616.69 USD
2/9/202616.71 USD
2/8/202616.95 USD
2/6/202616.85 USD
2/5/202616.85 USD
2/4/202617.60 USD
2/3/202618.49 USD
2/2/202619.77 USD
2/1/202619.65 USD
1/30/202619.77 USD
1/29/202619.77 USD
1/28/202619.63 USD
1/27/202619.77 USD
1/26/202620.55 USD
1/25/202620.43 USD
1/23/202619.82 USD
1/22/202619.82 USD
1/21/202620.37 USD
1/20/202618.78 USD
1/19/202619.10 USD
1/16/202618.72 USD
1/15/202618.72 USD
1/14/202619.00 USD
1/13/202619.28 USD
1/12/202619.31 USD
1/11/202619.51 USD
1/9/202616.84 USD
1/8/202616.84 USD
1/7/202617.05 USD
1/6/202617.88 USD
1/5/202617.22 USD
1/4/202617.28 USD
1/2/202617.00 USD
1/1/202617.00 USD
12/31/202517.35 USD
12/30/202517.35 USD
12/29/202517.55 USD
12/28/202517.79 USD
12/26/202517.85 USD
12/25/202517.85 USD
12/24/202517.82 USD
12/23/202517.82 USD
12/22/202517.90 USD
12/21/202518.60 USD
12/19/202518.17 USD
12/18/202518.17 USD
12/17/202517.63 USD
12/16/202517.23 USD
12/15/202517.02 USD
12/14/202516.77 USD
12/12/202516.50 USD
12/11/202516.50 USD
12/10/202516.48 USD
12/9/202516.82 USD
12/8/202515.88 USD
12/7/202515.98 USD
12/5/202515.76 USD
12/4/202515.76 USD
12/3/202518.66 USD
12/2/202518.31 USD
12/1/202519.97 USD
11/30/202520.13 USD
11/28/202521.01 USD
11/27/202521.01 USD
11/26/202521.07 USD
11/25/202521.07 USD
11/24/202521.71 USD
11/23/202521.86 USD
11/21/202519.89 USD
11/20/202519.89 USD
11/19/202517.44 USD
11/18/202516.19 USD
11/17/202514.69 USD
11/16/202514.65 USD
11/14/202515.07 USD
11/13/202515.07 USD
11/12/202515.11 USD
11/11/202515.49 USD
11/10/202515.53 USD
11/9/202515.72 USD
11/7/202515.80 USD
11/6/202515.80 USD
11/5/202516.63 USD
11/4/202518.80 USD
11/3/202518.08 USD
11/2/202518.53 USD
10/31/202518.55 USD
10/30/202518.55 USD
10/29/202518.07 USD
10/28/202517.95 USD
10/27/202518.06 USD
10/26/202518.29 USD
10/23/202518.40 USD
10/22/202518.34 USD
10/21/202517.58 USD
10/20/202518.54 USD
10/19/202519.05 USD
10/16/202517.42 USD
10/15/202518.45 USD
10/14/202518.28 USD
10/13/202516.65 USD
10/12/202516.56 USD
10/9/202516.21 USD
10/8/202516.72 USD
10/7/202516.62 USD
10/6/202515.33 USD
10/5/202515.46 USD
10/2/202515.37 USD
10/1/202515.22 USD
9/30/202515.56 USD
9/29/202515.99 USD
9/28/202514.38 USD
9/25/202514.13 USD
9/24/202514.03 USD
9/23/202513.70 USD
9/22/202514.89 USD
9/21/202514.90 USD
9/18/202514.28 USD
9/17/202514.71 USD
9/16/202513.70 USD
9/15/202513.80 USD
9/14/202513.98 USD
9/11/202513.47 USD
9/10/202514.42 USD
9/9/202513.27 USD
9/8/202513.47 USD
9/7/202513.40 USD
9/4/202513.73 USD
9/3/202513.91 USD
9/2/202513.73 USD
9/1/202513.72 USD
8/28/202514.08 USD
8/27/202514.22 USD
8/26/202513.86 USD
8/25/202513.68 USD
8/24/202513.54 USD
8/21/202513.89 USD
8/20/202513.50 USD
8/19/202513.14 USD
8/18/202513.42 USD
8/17/202513.26 USD
8/14/202513.93 USD
8/13/202513.81 USD
8/12/202513.89 USD
8/11/202513.53 USD
8/10/202512.98 USD
8/7/202513.04 USD
8/6/202513.40 USD
8/5/202512.49 USD
Access this data via the Eulerpool API
Get Free API Key

Adaptive Biotechnologies Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
155.90 M USD
-227.04 M USD
-225.25 M USD
Jan 1, 2024
167.38 M USD
-162.55 M USD
-159.49 M USD
Jan 1, 2025
265.20 M USD
-57.12 M USD
-59.50 M USD
Jan 1, 2026 (e)
286.58 M USD
-229.22 M USD
-70.07 M USD
Jan 1, 2027 (e)
352.18 M USD
-281.69 M USD
-35.54 M USD
Jan 1, 2028 (e)
430.23 M USD
-344.12 M USD
-11.96 M USD
Jan 1, 2029 (e)
524.90 M USD
-419.84 M USD
6.92 M USD
Jan 1, 2030 (e)
658.00 M USD
-526.30 M USD
1.54 M USD

Adaptive Biotechnologies Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 5, 2026, 2:20 AM
 
REVENUEM USD
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM USD
EBITM USD
EBIT MARGIN%
NET INCOMEM USD
NET INCOME GROWTH%
SHARESM
2017201820192020202120222023202420252026e2027e2028e2029e2030e
38.0055.0085.0098.00154.00185.00170.00178.00276.00286.00352.00430.00524.00658.00
–44.7454.5515.2957.1420.13-8.114.7155.063.6223.0822.1621.8625.57
57.8963.6472.9476.5368.1868.6555.2959.5574.2874.2874.2874.2874.2874.28
22.0035.0062.0075.00105.00127.0094.00106.00205.00212.43261.45319.38389.20488.73
-44.00-49.00-78.00-152.00-208.00-200.00-227.00-162.00-57.00-229.00-281.00-344.00-419.00-526.00
-115.79-89.09-91.76-155.10-135.06-108.11-133.53-91.01-20.65-80.07-79.83-80.00-79.96-79.94
-42.00-46.00-68.00-146.00-207.00-200.00-225.00-159.00-59.00-70.00-35.00-11.006.001.00
–9.5247.83114.7141.78-3.3812.50-29.33-62.8918.64-50.00-68.57-154.55-83.33
12.00105.88124.40136.95141.23143.05144.90147.10153.13153.13153.13153.13153.13153.13
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Adaptive Biotechnologies generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Adaptive Biotechnologies retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Adaptive Biotechnologies's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Adaptive Biotechnologies has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Adaptive Biotechnologies's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Adaptive Biotechnologies stock margins

The Adaptive Biotechnologies margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Adaptive Biotechnologies. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Adaptive Biotechnologies.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
68.06 %
-135.39 %
-134.30 %
Jan 1, 2022
70.36 %
-110.56 %
-110.56 %
Jan 1, 2023
60.76 %
-145.63 %
-144.48 %
Jan 1, 2024
63.85 %
-97.12 %
-95.29 %
Jan 1, 2025
77.53 %
-21.54 %
-22.44 %
Jan 1, 2026 (e)
77.53 %
-79.98 %
-24.45 %
Jan 1, 2027 (e)
77.53 %
-79.98 %
-10.09 %
Jan 1, 2028 (e)
77.53 %
-79.98 %
-2.78 %

Adaptive Biotechnologies Stock Revenue, EBIT, Earnings per Share

The Adaptive Biotechnologies earnings per share therefore indicates how much revenue Adaptive Biotechnologies has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2021
1.09 USD
-1.48 USD
-1.47 USD
Jan 1, 2022
1.27 USD
-1.40 USD
-1.40 USD
Jan 1, 2023
1.08 USD
-1.57 USD
-1.55 USD
Jan 1, 2024
1.14 USD
-1.11 USD
-1.08 USD
Jan 1, 2025
1.73 USD
-0.37 USD
-0.39 USD
Jan 1, 2026 (e)
1.86 USD
-1.50 USD
-0.46 USD
Jan 1, 2027 (e)
2.29 USD
-1.84 USD
-0.23 USD
Jan 1, 2028 (e)
2.80 USD
-2.25 USD
-0.08 USD

Adaptive Biotechnologies business model & stock analysis

Adaptive Biotechnologies Corp is a biotechnology company specializing in the discovery and development of therapies for various diseases. It was founded in 2009 by brothers Chad and Harlan Robins in Seattle, USA. Adaptive Biotechnologies Corp is a leading provider of immune sequencing technology and analysis of T-cell and B-cell receptors. The company's business model is based on the development of therapies through the analysis of patient samples. The company's artificial intelligence and machine learning make immune systems visible to fight pathogens. By creating an accurate profile of patients' immune systems, the company enables the development of personalized therapies tailored to the individual needs and disease profiles of patients. The company is divided into several divisions, including oncology, immunology, and research and development of therapeutics. In the field of oncology, Adaptive Biotechnologies Corp focuses on the discovery of cancer therapies by identifying T-cell receptor characteristics of patients who have responded to cancer treatments. The team at Adaptive Biotechnologies Corp works with various pharmaceutical and biotech companies to advance the discovery of cancer therapeutics. In the field of immunology, the company has also focused on the identification of rare and severe immune disorders to enable more targeted diagnostics and treatment. Adaptive Biotechnologies Corp provides immune and other research instruments and sample processing systems for the study of antigen-antibody interactions. In addition, the company has also developed its own products, including the ImmunTraCkeR® test system, which analyzes the immune response of critically ill patients to improve ongoing therapies or enable early detection of new diseases. Other products include the immunoSEQ® assay kit and the clonoSEQ® assay kit, which are used for sequencing patients' immune systems. These test systems allow for the detection of minimal residual routes of T-cell or B-cell receptors in patients' blood, enabling better monitoring of cancer and the creation of personalized treatment plans. Adaptive Biotechnologies Corp is particularly highly regarded in the pharmaceutical and biotech industry for novel therapeutics and biologics, and has already collaborated with many reputable companies including Genentech, Roche, and Microsoft. The company's mission is to accelerate progress in medical research and the development of new therapies to help patients around the world. In recent times, the company has played a crucial role in testing point-of-care COVID rapid tests. For example, it is working with universities such as the University of Pennsylvania to explore ways in which the tests can be utilized. The company is also developing its own COVID-19 tests that have undergone clinical testing. Overall, Adaptive Biotechnologies Corp is a successful biotechnology company with a unique focus on personalized medicine and therapies tailored to specific patient immune profiles. With its innovative products and services, as well as partnerships with industry leaders, the company has revolutionized the bio-IT world and become one of the leading companies in the industry.

Adaptive Biotechnologies SWOT Analysis

Strengths

  • Advanced technology in immune-driven medicine and genomics.
  • Strong and diversified intellectual property portfolio.
  • Robust partnerships and collaborations with leading pharmaceutical and biotech companies.
  • Highly skilled and experienced team of scientists and clinicians.

Weaknesses

  • Dependence on a limited number of key partners for revenue generation.
  • Vulnerability to competition and rapid technological advancements in the industry.
  • Regulatory challenges and uncertainties in the field of personalized medicine.

Opportunities

  • Growing demand for personalized medicine and precision diagnostics.
  • Exploration of immune-driven therapies for various diseases with potential for high efficacy.
  • Expansion into emerging markets with unmet healthcare needs.

Threats

  • Intense competition from established and emerging players in the biotechnology sector.
  • Potential regulatory barriers and reimbursement challenges for novel diagnostic tests.
  • Economic downturns and fluctuations affecting healthcare spending and research funding.

Adaptive Biotechnologies Employees

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Adaptive Biotechnologies Employees
Details
Date
Adaptive Biotechnologies Employees
Jan 1, 2019
- Employees
Jan 1, 2020
- Employees
Jan 1, 2021
- Employees
Jan 1, 2022
- Employees
Jan 1, 2023
- Employees
Jan 1, 2024
- Employees
Jan 1, 2025
- Employees

Adaptive Biotechnologies Segments

Adaptive Biotechnologies Revenue by Segment (1/4)

  • 3 Years

  • 5 Years

  • Max

Service
Service Revenue
Development support revenue
Immune Medicine Service Revenue
Collaboration Revenue
Regulatory Milestone Revenue
Development revenue regulatory milestones
Details
Date
Service
Service Revenue
Development support revenue
Immune Medicine Service Revenue
Collaboration Revenue
Regulatory Milestone Revenue
Development revenue regulatory milestones
Jan 1, 2019
0.00 USD
0.00 USD
39.55 M USD
0.00 USD
0.00 USD
0.00 USD
2.00 M USD
Jan 1, 2020
0.00 USD
0.00 USD
54.44 M USD
0.00 USD
0.00 USD
0.00 USD
2.50 M USD
Jan 1, 2021
0.00 USD
0.00 USD
65.45 M USD
0.00 USD
0.00 USD
0.00 USD
10.00 M USD
Jan 1, 2022
0.00 USD
81.14 M USD
0.00 USD
0.00 USD
66.39 M USD
6.00 M USD
0.00 USD
Jan 1, 2024
19.98 M USD
0.00 USD
0.00 USD
0.00 USD
13.45 M USD
12.50 M USD
0.00 USD
Jan 1, 2025
0.00 USD
0.00 USD
0.00 USD
41.30 M USD
0.00 USD
0.00 USD
0.00 USD

Adaptive Biotechnologies Revenue by Segment (2/4)

  • 3 Years

  • Max

Immune medicine service revenue
Details
Date
Immune medicine service revenue
Jan 1, 2019
0.00 USD
Jan 1, 2020
0.00 USD
Jan 1, 2021
0.00 USD
Jan 1, 2022
700,000.00 USD
Jan 1, 2024
13.50 M USD
Jan 1, 2025
0.00 USD

Adaptive Biotechnologies Revenue by Segment (3/4)

  • 3 Years

  • 5 Years

  • Max

Sequencing revenue
Development revenue
Details
Date
Sequencing revenue
Development revenue
Jan 1, 2019
43.52 M USD
41.55 M USD
Jan 1, 2020
41.44 M USD
56.94 M USD
Jan 1, 2021
78.90 M USD
300,000.00 USD
Jan 1, 2022
0.00 USD
0.00 USD
Jan 1, 2024
0.00 USD
0.00 USD
Jan 1, 2025
0.00 USD
0.00 USD

Adaptive Biotechnologies Revenue by Segment (4/4)

  • Max

Service
Collaboration Revenue
Service and Licensing Revenue
Regulatory Milestone Revenue
Details
Date
Service
Collaboration Revenue
Service and Licensing Revenue
Regulatory Milestone Revenue
Jan 1, 2019
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2020
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2021
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2022
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2024
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2025
192.83 M USD
41.28 M USD
23.36 M USD
19.50 M USD

Adaptive Biotechnologies Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Adaptive Biotechnologies historical P/E ratio, EBIT multiple, and P/S ratio

Adaptive Biotechnologies annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Adaptive Biotechnologies shares outstanding

The number of shares of Adaptive Biotechnologies was 153.13 M in 2025. This indicates how many shares Adaptive Biotechnologies is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2021
141.23 M Stocks
Jan 1, 2022
143.05 M Stocks
Jan 1, 2023
144.90 M Stocks
Jan 1, 2024
147.10 M Stocks
Jan 1, 2025
153.13 M Stocks
Jan 1, 2026 (e)
153.13 M Stocks
Jan 1, 2027 (e)
153.13 M Stocks
Jan 1, 2028 (e)
153.13 M Stocks

Current Adaptive Biotechnologies forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.00 %
Buy
85.71 % (12)
Hold
14.29 % (2)
Sell
0.00 % (0)
12M Price Target
20.40
Last Price
23.77
Currency
USD
12M Return Potential
-14.18 %
LTM Return
0 %

Adaptive Biotechnologies Analyst Rating Actions

DateFirmActionRatingReliability
7/30/2026
TD Cowen
TD Cowen
MaintainedBuy60
7/30/2026
Morgan Stanley
Morgan Stanley
MaintainedEqual Weight60
7/30/2026
Guggenheim
Guggenheim
MaintainedBuy30
7/30/2026
BTIG
BTIG
MaintainedBuy–
7/9/2026
Morgan Stanley
Morgan Stanley
MaintainedEqual Weight60
6/29/2026
Guggenheim
Guggenheim
MaintainedBuy30
6/17/2026
BTIG
BTIG
MaintainedBuy–
5/12/2026
Morgan Stanley
Morgan Stanley
MaintainedEqual Weight60
5/6/2026
TD Cowen
TD Cowen
MaintainedBuy60
5/6/2026
JP Morgan
JP Morgan
MaintainedOverweight80

Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.

Adaptive Biotechnologies Earnings Calls

2025

Adaptive Biotechnologies Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
7/29/2026-0.14USD-67.36 MUSD-2026 Q2
5/6/2026-0.16USD-62.07 MUSD-2026 Q1
2/5/2026-0.18USD-60.58 MUSD-2025 Q4
11/7/2024-0.29USD-41.12 MUSD-2024 Q3
5/1/2024-0.34USD-46.90 MUSD-2024 Q1
2/12/2024-0.30USD-50.66 MUSD-2023 Q4
8/1/2023-0.38USD-54.78 MUSD-2023 Q2
5/2/2023-0.42USD-44.68 MUSD-2023 Q1
2/13/2023-0.36USD-56.39 MUSD-2022 Q4
11/3/2022-0.38USD-48.75 MUSD-2022 Q3

EESG©

Eulerpool ESG Scorecard© for the Adaptive Biotechnologies stock

37/100
35
Environment
68
Social
8
Governance
E

Environment

20
Scope 1 - Direct Emissions—
Scope 2 - Indirect emissions from purchased energy—
Scope 3 - Indirect emissions within the value chain—
Total CO₂ emissions—
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees—
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Adaptive Biotechnologies shareholder structure

% Name
19.50430%
VIKING GLOBAL INVESTORS LP
VIKING GLOBAL INVESTORS LP
8.65069%
BLACKROCK, INC.
BLACKROCK, INC.
3.96290%
VANGUARD CAPITAL MANAGEMENT LLC
VANGUARD CAPITAL MANAGEMENT LLC
3.53539%
WESTFIELD CAPITAL MANAGEMENT CO LP
WESTFIELD CAPITAL MANAGEMENT CO LP
2.92071%
VANGUARD PORTFOLIO MANAGEMENT LLC
VANGUARD PORTFOLIO MANAGEMENT LLC
2.89379%
INVESCO LTD.
INVESCO LTD.
...

Adaptive Biotechnologies Beneficial Ownership Filings (SEC 13D/G)

Free Float
97.0%
Float Shares
-
Shares Outstanding
-
StakeHolderFiling
21.90%
S. Shabet
S. Shabet
SEC ↗
21.90%
C. Ott
C. Ott
SEC ↗
21.90%
Andreas Halvorsen
Andreas Halvorsen
SEC ↗
18.80%
VIKING GLOBAL INVESTORS LP
VIKING GLOBAL INVESTORS LP
SEC ↗
16.10%
Viking Global Performance LLC
Viking Global Performance LLC
SEC ↗
15.80%
Viking Global Equities Master Ltd.
Viking Global Equities Master Ltd.
SEC ↗
9.76%
David Rosen
David Rosen
SEC ↗
8.20%
Matrix Capital Management Company LP
Matrix Capital Management Company LP
SEC ↗
8.20%
David E. Goel
David E. Goel
SEC ↗
7.90%
BlackRock, Inc.
BlackRock, Inc.
SEC ↗

Adaptive Biotechnologies Executives and Management Board

12 members · avg. age 53 · 50 % women

CR

Mr. Chad Robins (50)

Chairman of the Board, Chief Executive Officer, Co-Founder · since 2009

4.97 M USD

Management

HR

Dr. Harlan Robins (52)

Co-Founder, Chief Scientific Officer

4.54 M USD
JR

Ms. Julie Rubinstein (53)

President, Chief Operating Officer

2.64 M USD
SB

Dr. Sharon Benzeno (51)

Chief Commercial Officer - Immune Medicine

1.80 M USD
KP

Mr. Kyle Piskel (41)

Chief Financial Officer

1.29 M USD
FL

Mr. Francis Lo (44)

Chief People Officer

–
SB

Ms. Susan Bobulsky (44)

Chief Commercial Officer - MRD

–

Board of Directors

PN

Mr. Peter Neupert (69)

Lead Independent Director

355,000.00 USD
MG

Ms. Michelle Griffin (59)

Independent Director

330,000.00 USD
RH

Dr. Robert Hershberg (62)

Independent Director

325,000.00 USD
KO

Dr. Katey Owen (56)

Independent Director

310,000.00 USD

Adaptive Biotechnologies Supply Chain

Adaptive Biotechnologies Supply Chain

Correlation: how closely stock prices move together

Same directionNo relationOpposite
7 companies
#Nameβ 1YTrend
1
Professional Diversity
Supplier·Interactive Media & Services·US
0.32
0.74
0.81
0.40
0.86
0.60
—
2
Nykode Therapeutics
Supplier·Customer·Biotechnology·NO
0.07
0.63
0.87
0.96
0.83
0.37
—
3
Illumina
Supplier·Customer·Life Sciences Tools & Services·US
0.57
0.87
0.88
0.76
0.88
0.31
0.59
#Nameβ 1YTrend
1
AstraZeneca
Supplier·Customer·Pharmaceuticals·GB
0.54
0.75
-0.45
-0.76
-0.68
-0.74
-0.32
2
Microsoft
Supplier·Customer·Software·US
0.52
0.41
0.29
0.83
-0.21
-0.72
-0.09
3
Roche Holding
Supplier·Customer·Pharmaceuticals·CH
0.43
0.64
-0.45
0.13
-0.32
-0.72
-0.14
4
Laboratory Corp
Supplier·Customer·Health Care Providers & Services·US
0.04
0.47
0.80
0.91
0.63
-0.51
0.24

Frequently asked questions about Adaptive Biotechnologies

The business model of Adaptive Biotechnologies Corp revolves around leveraging their proprietary immune medicine platform to develop and commercialize innovative diagnostic tests and therapeutics for various diseases. By using high-throughput sequencing to study the adaptive immune system, the company aims to understand and decode the high complexity of immune responses. This enables them to identify and analyze the biomarkers related to various diseases, including cancer and infectious diseases, resulting in the development of targeted diagnostic tools and potential treatment options. With their focus on precision medicine, Adaptive Biotechnologies Corp aims to improve patient outcomes and contribute to the advancement of personalized healthcare.

Adaptive Biotechnologies Corp is primarily active in the biotechnology industry.

Adaptive Biotechnologies Corp faces competition from various companies in the market. Some notable competitors include Pacific Biosciences of California Inc., Illumina Inc., Guardant Health Inc., and QIAGEN N.V. These companies also operate in the field of biotechnology, focusing on next-generation sequencing technologies and providing molecular diagnostic solutions. However, Adaptive Biotechnologies Corp distinguishes itself through its innovative and proprietary immune medicine platform, enabling the study of immune systems. By leveraging its unique technology, Adaptive Biotechnologies Corp maintains a competitive edge in the market.

Adaptive Biotechnologies Corp is a healthcare company specializing in decoding the adaptive immune system to improve patient care. Founded in 2009 by Chad Robins and Harlan Robins, the company's innovative approach focuses on combining high-throughput sequencing with advanced bioinformatics to study the immune system and enable discoveries in various disease areas. Adaptive Bio has collaborations with leading pharmaceutical companies and research institutions worldwide. With its deep understanding of the adaptive immune system, the company aims to develop revolutionary diagnostics and therapies for diseases like cancer, autoimmune disorders, and infectious diseases. Adaptive Biotechnologies Corp is committed to transforming medicine through its cutting-edge technologies and unique insights into the immune system.

Some significant milestones achieved by Adaptive Biotechnologies Corp include the successful completion of their initial public offering (IPO) in June 2019, raising approximately $345 million. They have also entered into collaborations and partnerships with notable organizations, such as Genentech, Microsoft, and Amgen, among others. Adaptive Biotechnologies Corp has made significant advancements in deciphering the adaptive immune system with their proprietary immune medicine platform. This has led to the development of groundbreaking diagnostic tools and therapeutics for various diseases, including cancer. They continue to expand their reach globally and are committed to advancing precision medicine through their innovative approach to harnessing the power of the immune system.

Adaptive Biotechnologies Corp is primarily present in the United States.

Adaptive Biotechnologies Corp represents a strong commitment to revolutionizing the diagnosis and treatment of diseases through its innovative biotechnology solutions. The company's corporate philosophy revolves around harnessing the power of the adaptive immune system to develop precise and accurate diagnostic tests and personalized therapeutics for various diseases. Adaptive Biotechnologies Corp strives to improve patient outcomes by combining cutting-edge technology, computational biology, and extensive research expertise. With an unwavering focus on advancing precision medicine, Adaptive Biotechnologies Corp aims to empower healthcare professionals with the tools they need to make informed decisions and improve the lives of patients.

Analysts currently set an average price target of 20.40 USD for the Adaptive Biotechnologies stock (median: 20.40 USD), implying -14.2 % versus the latest price. The consensus is based on 14 analyst ratings.

Adaptive Biotechnologies Analyst Price Targets 2026

14 analysts currently rate the Adaptive Biotechnologies stock: 12 recommend buying, 2 holding and 0 selling. For 2026, analysts expect Adaptive Biotechnologies to generate revenue of 286.58 M USD and earnings per share of -0.46 USD.

Adaptive Biotechnologies Analyst Price Targets 2026

Converted at the current exchange rate, the Adaptive Biotechnologies share trades at 19.61 EUR (22.57 USD).

The Adaptive Biotechnologies share (ADPT) is listed on 5 stock exchanges, including: NASDAQ (ADPT), XETRA (1HM.DE), Frankfurt (1HM.F), München (1HM.MU), Düsseldorf (1HM.DU).

Adaptive Biotechnologies Corp is a biomedical company that focuses on the development of diagnostic tests and therapies to combat cancer and infectious diseases. The company was founded in 2009 and is headquartered in Seattle, Washington.

The expected revenue of Adaptive Biotechnologies is 286.58 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Adaptive Biotechnologies is -70.07 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Adaptive Biotechnologies is currently -49.33. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Adaptive Biotechnologies stock.

The price-to-sales ratio (P/S) of Adaptive Biotechnologies is currently 12.06. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Adaptive Biotechnologies stock.

The Eulerpool Quality Score for Adaptive Biotechnologies is 3/10.

The ISIN of Adaptive Biotechnologies is US00650F1093. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Adaptive Biotechnologies is A2PLR5. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Adaptive Biotechnologies is ADPT. The ticker symbol is used to trade Adaptive Biotechnologies shares on the stock exchange.

Adaptive Biotechnologies paid dividends every year for the past 0 years.

Adaptive Biotechnologies is assigned to the 'Health' sector.

The dividends of Adaptive Biotechnologies are distributed in USD.

All fundamentals and in-depth analysis of Adaptive Biotechnologies

Our stock analysis for Adaptive Biotechnologies stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Adaptive Biotechnologies. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Adaptive Biotechnologies Stock
Adaptive Biotechnologies Revenue→
Adaptive Biotechnologies Stock
Adaptive Biotechnologies Net Income→
Adaptive Biotechnologies Stock
Adaptive Biotechnologies P/E→
Adaptive Biotechnologies Stock
Adaptive Biotechnologies P/S→
Adaptive Biotechnologies Stock
Adaptive Biotechnologies EBIT→
Adaptive Biotechnologies Stock
Adaptive Biotechnologies Dividend→
Adaptive Biotechnologies Stock
Adaptive Biotechnologies Directors Dealings→
Adaptive Biotechnologies Stock
Adaptive Biotechnologies Stocks→
Adaptive Biotechnologies Stock
Adaptive Biotechnologies Market capitalization→
Adaptive Biotechnologies Stock
Adaptive Biotechnologies Debt→
Adaptive Biotechnologies Stock
Adaptive Biotechnologies Liabilities→
Adaptive Biotechnologies Stock
Adaptive Biotechnologies Equity→
Adaptive Biotechnologies Stock
Adaptive Biotechnologies AAQS→
Adaptive Biotechnologies Stock
Adaptive Biotechnologies Employees→
Adaptive Biotechnologies Stock
Adaptive Biotechnologies ROE→
Adaptive Biotechnologies Stock
Adaptive Biotechnologies ROA→
Adaptive Biotechnologies Stock
Adaptive Biotechnologies ROCE→
Adaptive Biotechnologies Stock
Adaptive Biotechnologies News→
Adaptive Biotechnologies Stock
Adaptive Biotechnologies Analyst Price Targets→

Health Stocks

ADBiotech CoAdapthealthADC TherapeuticsAdaltaAddex TherapeuticsAdageneAddex TherapeuticsAcutus MedicalAddLifeAcutaas ChemicalsAddus HomecareAcusphereAll Stocks A–Z →